BetaGlue Technologies

Milano, Italy Founded: 2017 • Age: 9 yrs
A radiotherapy platform for solid tumor treatment is developed.

About BetaGlue Technologies

BetaGlue Technologies is a company based in Milano (Italy) founded in 2017.. BetaGlue Technologies has raised $18.91 million across 2 funding rounds from investors including Profectus Capital, European Commission and Liftt. BetaGlue Technologies offers products and services including YntraDose. BetaGlue Technologies operates in a competitive market with competitors including EMulate Therapeutics, CNRT, RITA Medical Systems, Phosphorex and Trod Medical, among others.

  • Headquarter Milano, Italy
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Betaglue Therapeutics Spa
Operational Areas
Healthcare → Pharmaceuticals & Therapeutics
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $18.91 M (USD)

    in 2 rounds

  • Latest Funding Round
    $8.71 M (USD), Series A

    Jun 07, 2024

  • Investors
  • Employee Count
    Employee Count
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of BetaGlue Technologies

BetaGlue Technologies offers a comprehensive portfolio of products and services, including YntraDose. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Platform for targeted and personalized treatment of solid tumours.

People of BetaGlue Technologies
Headcount 10-50
Employee Profiles 2
Employee Profiles
People
Mike Cogswell
Chairman Of The Board
People
Luca Melindo
Non Executive Director - Chairman Remuneration Committee

Unlock access to complete

Teams

Unlock access to complete

Funding Insights of BetaGlue Technologies

BetaGlue Technologies has successfully raised a total of $18.91M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $8.71 million completed in June 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 2
  • Last Round Series A — $8.7M
  • First Round

    (20 Jul 2022)

  • Investors Count 9
Date Amount Transaction Name Valuation Lead Investors Investors
Jun, 2024 Amount Series A - BetaGlue Technologies Valuation Neva SGR , LIFTT
Jul, 2022 Amount Series A - BetaGlue Technologies Valuation Fin Posillipo , Kairos
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in BetaGlue Technologies

BetaGlue Technologies has secured backing from 9 investors, including institutional and venture fund investors. Prominent investors backing the company include Profectus Capital, European Commission and Liftt. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Venture capital firm focused on multiple sectors
Founded Year Domain Location
Neva SGR is engaged in venture capital investments globally.
Founded Year Domain Location
VC firm investing in seed and early stage companies in Italy
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by BetaGlue Technologies

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - BetaGlue Technologies

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Betaglue Technologies Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of BetaGlue Technologies

BetaGlue Technologies operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as EMulate Therapeutics, CNRT, RITA Medical Systems, Phosphorex and Trod Medical, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Radiofrequency devices for cancer treatment are developed using ultra-low energy.
domain founded_year HQ Location
Medical isotopes are supplied for tumor diagnosis and treatment.
domain founded_year HQ Location
Oncology therapy products, including ablation and embolization systems, are developed.
domain founded_year HQ Location
Polymeric nanospheres, microspheres, and drug delivery solutions are developed.
domain founded_year HQ Location
Develops innovative RF-based focal ablation devices for tumor treatment.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Betaglue Technologies

Frequently Asked Questions about BetaGlue Technologies

When was BetaGlue Technologies founded?

BetaGlue Technologies was founded in 2017 and raised its 1st funding round 5 years after it was founded.

Where is BetaGlue Technologies located?

BetaGlue Technologies is headquartered in Milano, Italy.

Who is the current CEO of BetaGlue Technologies?

Antonino Amato is the current CEO of BetaGlue Technologies.

Is BetaGlue Technologies a funded company?

BetaGlue Technologies is a funded company, having raised a total of $18.91M across 2 funding rounds to date. The company's 1st funding round was a Series A of $10.21M, raised on Jul 20, 2022.

What does BetaGlue Technologies do?

BetaGlue Technologies was founded in 2017 in Milano, Italy, within the medical devices sector. A proprietary platform is developed, combining radioactive glue, β-emitting radiotherapy, and external beam radiation therapy. This system targets patients with solid tumors and various cancers. A drug delivery mechanism is also included in the operations, focusing on oncology treatments.

Who are the top competitors of BetaGlue Technologies?

BetaGlue Technologies's top competitors include EMulate Therapeutics, Phosphorex and CNRT.

What products or services does BetaGlue Technologies offer?

BetaGlue Technologies offers YntraDose.

Who are BetaGlue Technologies's investors?

BetaGlue Technologies has 9 investors. Key investors include Profectus Capital, European Commission, Liftt, Kairos Partners, and Fin Posillipo.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available